 | BMTinfoNet bmtinfonet.org
Highly recommended.
A nonprofit that specializes in SCT information and support.
|
 | Bone Marrow Transplant (BMT)
makna.org
|
 |
|
 |
Managing Indolent Lymphomas in Relapse asheducation.org
Working Our Way Through a Plethora of Options (includes SCT
guidance)
|
 |
|
 | High-Dose Therapy and Autologous Hematopoietic-Cell Transplantation for Follicular Lymphoma Beyond First
Remission: The Stanford University Experience - Biology of Blood and Marrow Transplantation 7:294-301 (2001)
PDF | PDF-Help
|
 | SCT for
Low grade Lymphoma asheducationbook.org
/2004 full text | PAL's
readable version
"In Section III, Dr. Koen Van Besien provides a
well-documented update on outcomes associated with autologous
and allogeneic stem cell transplantation for FL. The results
of trials of autologous stem cell transplantation in first
remission and recent data supporting a role for graft purging
are discussed. Based on the premise that a
graft-versus-lymphoma effect is operative in FL,
reduced-intensity allogeneic transplantation is the preferred approach
in many cases, and recently reported results are summarized. Criteria
for patient selection and the optimal role of transplantation in
the overall therapeutic plan for the patient with FL are presented."
|
 | Support group for SCT
ACOR BMT-Talk Support
Groups
|
 |
Types of Transplants & Diseases Transplanted MSKCC
|
 | Survivorship & Support
MSKCC
|
 | Patient SCT Stories Cyberfamily
| What to take to Hospital
Cyberfamily
|
 | The Role of Autologous Transplantation in the Management of Mantle Cell Lymphoma:
A Study From the EBMT E. Vandenberghe, C. Ruiz de Elvira, P. Isaacson, E. Lopez-Guillermo, E. Conde,
C. Gisselbrecht, F. Guilhot, A. Goldstone, N. Schmitz PDF
| PDF-Help
|
 |
Outcome: Radioimmunotherapy with
131-I tositumomab (Bexxar) enhanced survival in good prognosis
relapsed and high-risk diffuse large B-cell lymphoma (DLBCL)
patients receiving high-dose chemotherapy and autologous stem cell
transplantation. ASCO
2007
Conclusions: The addition of 131-I tositumomab to BEAM
and autologous stem cell transplant for relapsed or high-risk
chemosensitive DLBCL produces a 3-yr OS of 81% without excess
toxicity. This compares favorably to historical controls. This
regimen is currently being tested in a phase III trial in the BMT/CTN
of Rituximab/BEAM vs. 131-I tositumomab/BEAM in patients with
relapsed chemosensitive DLBCL.
|
 |
Outcomes: High-Dose Therapy (HDT) and Autologous Stem-Cell Transplantation
(ASCT) in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome
J Clin Oncol. 2007 Dec 10; PMID: 18071187
This study shows that HDT and ASCT offers the possibility of
long-term disease-free survival to patients with AITL. Early
transplantation is necessary to achieve optimal results.
|
 | Pilot study: High activity
[escalating doses of] Zevalin® with peripheral blood progenitor
cells support [followed by ASCT] in patients with
refractory/resistant B-cell non-Hodgkin lymphomas blackwell-synergy.com
... high-activity Zevalin® with ASCT is feasible
and could be safely delivered in elderly and heavily pretreated
NHL patients, including those who previously received high-dose
chemotherapy and ASCT.
|
 | Expert review
Autologous transplantation for follicular lymphoma? Not too soon!
- bloodjournal.hematologylibrary.org
The overall role of ASCT in follicular lymphoma continues to
be debated. It is an excellent treatment option for the
management of younger patients with recurrent disease.4
In advanced newly diagnosed lymphoma, a survival
advantage has yet to be shown; with more prolonged
follow-up it may still emerge in the GLSG study.
|
 |
Harvesting stem cells: Intermediate
dose etoposide plus G-CSF 16 g/kg is more effective than
cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization
of lymphoma patients.
Leuk Lymphoma. 2007 Oct;48(10):1950-60. PMID:
17917963
Intermediate dose etoposide + G-CSF 16 microg/kg is a highly
effective mobilizing therapy, further, it has the advantage of low
hematologic toxicity and can be easily administered as outpatient
treatment.
|
 | Prognostic factors & auto SCT: The
pre-transplant FLIPI Index is associated with survival of
follicular lymphoma patients undergoing autologous stem cell
transplantation.
Leuk Lymphoma. 2007 Oct;48(10):1961-7. PMID:
17917964
The association of FLIPI with survival appeared to be more
relevant for patients who received standard conditioning regimens
compared to those that were treated with high-dose
radioimmunotherapy (p = 0.004).
Among all patients, mortality was also associated with
chemosensitive disease (HR = 0.47, p = 0.01) or untreated relapse
(HR = 0.20, p = 0.0002) vs. chemoresistant disease, and >/=2
extranodal sites (HR = 2.82, p = 0.03) after adjusting for
FLIPI.
These data suggest that the FLIPI and select non-FLIPI factors
after adjustment for the FLIPI are associated with survival in FL
patients undergoing ASCT.
|
 | The impact of histologic grade on the outcome of high-dose
therapy and autologous stem cell transplantation for follicular
lymphoma nature.com
|
 | High-Dose Bexxar® with Stem Cell Support Effective in
Elderly B-Cell NHL professional.cancerconsultants.com
"In the current study, 24 patients older than 60 years
with refractory or relapsed B-cell lymphoma were treated with
myeloablative doses of Bexxar followed by autologous stem cell
infusions. Patients in this study were a mixture of high and
low-grade NHL. This was a heavily pretreated group of patients and
over half were deemed resistant to treatment. These authors
reported a 3 year overall survival of 59% and a progression-free
survival of 51%. There were no treatment-related deaths and
toxicities were generally mild."
|
 |
Factors associated with outcomes in allogeneic hematopoietic
cell transplantation with nonmyeloablative conditioning [mini
alloSCT] after failed [conventional] myeloablative hematopoietic
cell transplantation.
J Clin Oncol. 2006 Sep 1;24(25):4150-7. Epub 2006 Aug 8. PMID:
16896000
Factors associated with better overall survival were PR or CR
(P = .01) and lack of comorbidity (P = .03) at HCT and absence of
acute GVHD after HCT (P = .06). CONCLUSION: Encouraging outcomes
were seen with allogeneic HCT after nonmyeloablative conditioning
in selected patients who had experienced relapse after a high-dose
HCT, particularly in patients with non-Hodgkin's lymphoma. Results
with unrelated grafts were comparable with results with related
grafts.
|
 |
A long-lasting third complete remission after
second autologous transplant followed by maintenance treatment
with rituximab in a patient with diffuse large cell non-Hodgkin's
lymphoma.
Am J Hematol. 2006 Aug 2: No abstract available. PMID: 16886214
|
 | A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab
tiuxetan in Combination with High-Dose Etoposide and
Cyclophosphamide Followed by Autologous Stem Cell Transplant in
Patients with Poor-Risk or Relapsed Non-Hodgkins Lymphoma (NHL).
Blood. 2005 Jul 7; PMID:
16002426
No outcome data, but ... "We conclude that high-dose (90)Y
ibritumomab tiuxetan can be combined safely with high-dose
etoposide and cyclophosphamide without increase in
transplant-related toxicity or delayed engraftment."
|
 |
Radioactive
Anti-CD 20 Antibody (Bexxar®) May Improve Outcome of Autologous
Transplants for Follicular Lymphomas
cancerconsultants.com
|
 | Phase I Trial of Iodine-131 Tositumomab (Bexxar) With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
jco.org
|
 | High-dose CEB vs BEAM with autologous stem cell transplant
in lymphoma. [BEAM is the winner.]
Bone Marrow Transplant. 2004 Jul 26 PMID:
15273714 | Related
abstracts
|
 | Myeloablative
radiochemotherapy followed by autologous stem cell transplantation
in first remission prolongs progression-free survival in
follicular lymphoma - results of a prospective randomized trial of
the German Low-Grade Lymphoma Study Group (GLSG). Blood. 2004 Jul PMID:
15238420
|
 | Rituxan®
Prior to Autologous Stem Cell Transplantation may Improve Outcomes
in non-Hodgkin's Lymphoma www.ufscc.ufl.edu
|
 | Autologous
bone marrow transplantation for marginal zone non-Hodgkin's
lymphoma.
Leuk Lymphoma. 2004 Feb;45(2):315-20. PMID:
15101717 | Related
abstracts
|
 | [872] Long Term Results of
Radioimmunotherapy with Bexxar/BEAM and Autologous Stem Cell
Transplantation (ASCT) for Chemotherapy Resistant Aggressive
ASH 2003
|
 | Auto SCT - treatment-related mortality: Effect
of cumulative etoposide doses on the outcome of autologous
peripheral-blood progenitor-cell transplantation for lymphoma.
Bone Marrow Transplant. 2004 Jan 19 PMID: 14730338
|
 | Auto SCT: Rituximab and ICE (RICE) as
second-line therapy prior to autologous stem cell transplantation
for relapsed or primary refractory diffuse large B-cell lymphoma.
Blood. 2004 Jan 22 PMID: 14739217
|
 |
|
 |
Immunotherapy
w/ autoBMT medscape
(free login req.)
|
 | CD34+-Enriched
Peripheral Blood Progenitor Cell Collections in Lymphoma Autotransplants
Are Associated With Increased Morbidity, Hillard M.
Lazarus et al. PDF
|
 |
Involved-Field
Radiation Therapy as an Adjunct to the Autotransplant Preparative
Regimen for Lymphoma
David P. Schenkein, et al. PDF
mmserver.cjp.com
|
 |
COMPARING WITH SALVAGE TREATMENT: Autologous bone
marrow transplantation as compared with salvage chemotherapy in relapses
of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med.
1995 Dec 7;333(23):1540-5. PMID: 7477169 PubMed
|
 |
FRONT LINE TREATMENT: Value of autologous stem cell
transplantation with purged bone marrow as first-line therapy for
follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Bone Marrow Transplant. 2000 Nov;26(9):971-7. PMID: 11100276 PubMed
|
 | EFFICACY DATA: Long-term follow-up of autologous bone marrow
transplantation in patients with relapsed follicular lymphoma. Blood.
1999 Nov 15;94(10):3325-33. PMID: 10552941 PubMed
abstract
|
 | EFFICACY DATA: High-dose therapy with autologous bone marrow support
as consolidation of remission in follicular lymphoma: long-term
clinical and molecular follow-up. J Clin Oncol. 2000 Feb;18(3):527-36.
PMID: 10653868 PubMed
abstract
|
 | OPTIMIZING: Improve the Outcome of Autologous Hematopoietic Cell
Transplantation! Karl G. Blume Stanford University School of
Medicine, Stanford, California WEB
| Full-PDF
| PDF-Help
|
 |
OPTIMIZING: Bcl-2
clearance: optimizing outcomes in follicular non-Hodgkin?s lymphoma Bone Marrow
Transplant
2002 Feb;29 Suppl 1:S14-S17. PMID: 11840156
|
 | REVIEW: Graft purging in autologous bone marrow
transplantation: a promise not quite fulfilled.
Oncology (Huntingt). 2004 Jun;18(7):867-76; discussion 876-8, 881,
884. Review. PMID:
15255171 | Related
articles
|
 | REVIEW: Role of autologous bone marrow transplantation in
non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 1993
Jun;7(3):577-90. Review. PMID: 8102135 PubMed
abstract
|
 |
REVIEW: Bone marrow transplantation for non-Hodgkin's lymphoma: a
review. Am J Med Sci. 1997 Apr;313(4):228-35. Review. PMID: 9099153 abstract
|
 | REVIEW: Biology of Blood and Marrow Transplantation (abstracts
for Lymphoma) www.bbmt.org
|